NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis → No Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for Free (From Hedgeye) (Ad) Free REPL Stock Alerts $7.90 +0.79 (+11.11%) (As of 06/7/2024 ET) Add Compare Share Share Today's Range$6.70▼$8.0450-Day Range$5.01▼$7.9052-Week Range$4.92▼$24.81Volume2.62 million shsAverage Volume1.03 million shsMarket Capitalization$485.22 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Replimune Group alerts: Email Address Replimune Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside111.0% Upside$16.67 Price TargetShort InterestBearish19.17% of Float Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment0.38Based on 12 Articles This WeekInsider TradingSelling Shares$593,409 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.25) to ($2.58) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector140th out of 904 stocksBiological Products, Except Diagnostic Industry13th out of 150 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days.Read more about Replimune Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted19.17% of the float of Replimune Group has been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Replimune Group has recently increased by 2.60%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 2.4 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 0.38. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Replimune Group this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for REPL on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $593,409.00 in company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.25) to ($2.58) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -2.44, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressTime is Running Out - June 25th Deadline Approaching!If you missed out on crypto, this could be your second chance. The AI “wealth window” is opening now, but you must get in now. Don’t delay.See all the details you need here. About Replimune Group Stock (NASDAQ:REPL)Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesMay 21, 2024 | insidertrades.comChristopher Sarchi Sells 2,218 Shares of Replimune Group, Inc. (NASDAQ:REPL) StockJune 8 at 5:21 AM | americanbankingnews.comBarclays Raises Replimune Group (NASDAQ:REPL) Price Target to $17.00June 7 at 8:12 AM | americanbankingnews.comReplimune Group (NASDAQ:REPL) Price Target Raised to $17.00June 7 at 8:00 AM | globenewswire.comReplimune to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 7 at 5:32 AM | americanbankingnews.comReplimune Group (NASDAQ:REPL) Receives Outperform Rating from WedbushJune 6 at 7:00 AM | globenewswire.comReplimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed MelanomaJune 3, 2024 | globenewswire.comReplimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | globenewswire.comReplimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 20, 2024 | markets.businessinsider.comBuy Rating Affirmed: Replimune’s Financial Stability and RP1’s Promising FutureMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Replimune Group Amidst Promising RP1 Developments and Strong Financial PositionMay 17, 2024 | markets.businessinsider.comBuy Recommendation for Replimune Group Based on Promising RP1 Clinical Developments and Robust Financial OutlookMay 16, 2024 | investorplace.comREPL Stock Earnings: Replimune Group Misses EPS for Q4 2024May 16, 2024 | globenewswire.comReplimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate UpdateApril 7, 2024 | globenewswire.comInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual MeetingApril 4, 2024 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 30, 2024 | bizjournals.comFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingMarch 29, 2024 | uk.investing.comReplimune appoints new CEO ahead of drug applicationMarch 28, 2024 | bizjournals.comPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealMarch 26, 2024 | marketwatch.comReplimune Names Sushil Patel as CEO in Broader ShakeupMarch 26, 2024 | markets.businessinsider.comReplimune Promotes Sushil Patel To Succeed Philip Astley-Sparke As CEOMarch 26, 2024 | globenewswire.comReplimune Announces Appointment of Sushil Patel to CEO and Executive Leadership TransitionsMarch 16, 2024 | finance.yahoo.comREPL Apr 2024 10.000 callMarch 15, 2024 | finance.yahoo.comREPL Mar 2024 10.000 putMarch 6, 2024 | finance.yahoo.comReplimune to Present at the American Association for Cancer Research Annual Meeting 2024March 5, 2024 | finance.yahoo.comReplimune to Present at Three Upcoming Investor ConferencesSee More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today6/08/2024Next Earnings (Estimated)8/01/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees284Year Founded2015Price Target and Rating Average Stock Price Target$16.67 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+111.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.62% Return on Assets-39.47% Debt Debt-to-Equity Ratio0.18 Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.10 per share Price / Book1.30Miscellaneous Outstanding Shares61,420,000Free Float48,764,000Market Cap$485.22 million OptionableOptionable Beta1.15 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Comp: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer Dr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Comp: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Comp: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Comp: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEAlloVirNASDAQ:ALVRAtara BiotherapeuticsNASDAQ:ATRATarsus PharmaceuticalsNASDAQ:TARSGinkgo BioworksNYSE:DNAView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 800 shares on 5/17/2024Ownership: 0.000%Redmile Group LLCSold 135,275 shares on 5/16/2024Ownership: 6.076%Robert CoffinSold 11,464 sharesTotal: $74,172.08 ($6.47/share)Philip Astley-SparkeSold 37,928 sharesTotal: $245,394.16 ($6.47/share)Colin LoveSold 17,615 sharesTotal: $113,969.05 ($6.47/share)View All Insider TransactionsView All Institutional Transactions REPL Stock Analysis - Frequently Asked Questions Should I buy or sell Replimune Group stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Replimune Group in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" REPL shares. View REPL analyst ratings or view top-rated stocks. What is Replimune Group's stock price target for 2024? 3 brokerages have issued 1 year price objectives for Replimune Group's stock. Their REPL share price targets range from $16.00 to $17.00. On average, they expect the company's stock price to reach $16.67 in the next year. This suggests a possible upside of 111.0% from the stock's current price. View analysts price targets for REPL or view top-rated stocks among Wall Street analysts. How have REPL shares performed in 2024? Replimune Group's stock was trading at $8.43 on January 1st, 2024. Since then, REPL stock has decreased by 6.3% and is now trading at $7.90. View the best growth stocks for 2024 here. When is Replimune Group's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our REPL earnings forecast. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings results on Thursday, May, 16th. The company reported ($0.82) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.04. What ETF holds Replimune Group's stock? Horizon Kinetics Medical ETF holds 14,396 shares of REPL stock, representing 0.44% of its portfolio. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some companies that other Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU), Pfizer (PFE), SCYNEXIS (SCYX), Exelixis (EXEL) and Fulcrum Therapeutics (FULC). When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Replimune Group's major shareholders? Replimune Group's stock is owned by many different institutional and retail investors. Top institutional shareholders include Price T Rowe Associates Inc. MD (10.67%), Redmile Group LLC (6.08%), Vanguard Group Inc. (4.51%), Clearbridge Investments LLC (0.45%), Nan Fung Group Holdings Ltd (0.33%) and Jacobs Levy Equity Management Inc. (0.22%). Insiders that own company stock include Andrew Schwendenman, Christopher Sarchi, Colin Love, Fund Iv LP Omega, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel and Tanya Lewis. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:REPL) was last updated on 6/8/2024 by MarketBeat.com Staff From Our PartnersCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredWarren Buffett & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Con...InvestorPlace | SponsoredThe new masters of energyAccording to one source, this new grid could soon provide energy to “one billion people in the world who don’t...Porter & Company | SponsoredWe’ve Made 1,000% … THREE Different Times in the Last Year (Here’s How)Bitcoin can and probably will hit the $1 MILLION level this decade. That’s more than 1,000% upside from the...Paradigm Press | SponsoredBreaking - The US Gov. Seized CITGODo you want an investment that can double or triple your money in the next three months? The US Court is cu...Augury Research | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | SponsoredTop 5 AI Stocks to Buy for 2024The electric vehicle boom is accelerating – and fast.Market Moving Trends | SponsoredNo Strings Attached: Get 30 Days of Hedgeye’s Top Stock Picks for FreeOptimize your stock investing strategy with Hedgeye's Investing Ideas, where rigorous fundamental stock analys...Hedgeye | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.